Navigation Links
AlphaRx Shareholder Update
Date:6/24/2009

MARKHAM, ON, June 24 /PRNewswire-FirstCall/ - AlphaRx Inc. (OTCBB: ALRX) releases letter to their shareholders:

Dear Shareholders,

We wanted to take a few minutes to update the current views on AlphaRx. For the first time in our corporate history, we ended our last quarter with a small profit. Aside from the fact that it was a small amount, it was significant on more than one front. The events that occurred over the past few weeks, have woke up investors around the world.

Our revenue is growing and our product pipeline remains robust and stronger than ever. We have 2 partnered products with potential milestone payments in excess of US$ 155 million which may generate a long-term stream of multi-million dollar royalty income. We at AlphaRx, have established research collaborations with leading specialty pharmaceutical companies and research institutions, such as the US Army. We have both benefited either financially or scientifically. Furthermore, these collaborations may lead to licensing agreements of our products.

We are in the forefront of nanomedicine development and we are poised to be the world's first pharmaceutical company to commercialize a polymeric-based nanomedicine for the treatment of nosocomial pneumonia.

Our goal, as it has been from Day number one, is to create profit for our shareholders and increase shareholder value. We believe we are succeeding. Thank you for your support. We will continue to keep you informed.

    Michael M. Lee

    President & CEO

About AlphaRx Inc.

AlphaRx is a specialty pharmaceutical company dedicated to developing proven therapies by reformulating FDA approved and marketed drugs which through the application of its proprietary site-specific nano drug delivery technology, offers improved medical benefits and a potential for significant commercial product development.

FORWARD LOOKING STATEMENTS:

This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company.


'/>"/>
SOURCE AlphaRx Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. AlphaRx and Gaia BioPharma Provide GAI-122 Development Update
2. AlphaRx Signs Cooperative Research and Development Agreement with US Army
3. AlphaRx Provides Corporate and Development Update
4. AlphaRxs Indaflex(TM) Continues its Clinical Development
5. AlphaRx CEO Accumulates More Company Shares
6. AlphaRx Officers and Directors To Exercise Options, Warrants and Retain Shares
7. AlphaRx Announces Debt Conversion
8. AlphaRx To Present at 47th Annual ICAAC
9. All Seven Members of RBC Life Sciences Board of Directors Were Re-Elected During the Companys 2009 Annual Shareholders Meeting
10. Aethlon Medical Releases Shareholder Letter to Discuss the Treatment of Hepatitis-C Virus (HCV)
11. The Quigley Corporation Announces Final Voting Results for 2009 Annual Meeting of Shareholders; Judge Orders Incumbent Board to Remain In Place Until Further Hearing; Final Outcome of Director Election Remains Uncertain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and San Francisco dentists, ... cutting-edge Oventus O2Vent technology. As many as 18 million Americans are estimated to ... breathing. Oral appliances can offer significant relief to about 75 percent of people ...
(Date:10/12/2017)... ... October 12, 2017 , ... The company ... of today’s consumer and regulatory authorities worldwide. From Children’s to Adults 50+, every ... meet the highest standard. , These products are also: Gluten Free, Non-GMO, ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... October 12, 2017 , ... Information about the technology: ... develop to enable prevention of a major side effect of chemotherapy in children. ... pediatric patients. For cisplatin, hearing loss is FDA listed on-label as a dose ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... HMP ... the recipient of a 2017 Folio Magazine Eddie Digital Award for ‘Best B-to-B Healthcare ... City on October 11, 2017. , The annual award competition recognizes editorial and design ...
Breaking Medicine News(10 mins):
(Date:9/28/2017)... 2017 Cohen Veterans Bioscience and Early Signal ... wearable and home sensors for real-time monitoring of patients ... a nonprofit organization focused on disruptive health solutions for ... analytical system to record and integrate behavioral, cognitive, physiological ... ...
(Date:9/25/2017)... , Sept. 25, 2017  EpiVax, Inc., ... vaccine design, and immune-engineering today announced the launch ... the development of personalized therapeutic cancer vaccines. EpiVax ... provided exclusive access to enabling technologies to the ... MBA will lead EpiVax Oncology as Chief Executive ...
(Date:9/19/2017)... HistoSonics, Inc., a venture-backed medical device company developing a non-invasive, robotically assisted, platform therapy that ... developments today:   ... ... Tom Tefft ... Veteran medical device executive Josh Stopek , PhD, who has led R&D and ...
Breaking Medicine Technology: